



# Alzheimer's disease genes and autophagy



Seung-Yong Yoon <sup>a,b,c,d,\*</sup>, Dong-Hou Kim <sup>a,b,c,d,\*</sup>

<sup>a</sup> Alzheimer's Disease Experts Lab (ADEL), Asan Institute of Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>b</sup> Department of Brain Science, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>c</sup> Bio-Medical Institute of Technology (BMIT), University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>d</sup> Cell Dysfunction Research Center (CDRC), University of Ulsan College of Medicine, Seoul, Republic of Korea

## ARTICLE INFO

### Article history:

Received 18 October 2015

Received in revised form

9 March 2016

Accepted 13 March 2016

Available online 23 March 2016

### Keywords:

Tau

APP

Amyloid

Presenilin

APOE

TREM2

## ABSTRACT

Autophagy is a process to degrade and recycle cellular constituents via the lysosome for regulating cellular homeostasis. Its dysfunction is now considered to be involved in many diseases, including neurodegenerative diseases. Many features reflecting autophagy impairment, such as autophagosome accumulation and lysosomal dysfunction, have been also revealed to be involved in Alzheimer's disease (AD). Recent genetic studies such as genome-wide association studies in AD have identified a number of novel genes associated with AD. Some of the identified genes have demonstrated dysfunction in autophagic processes in AD, while others remain under investigation. Since autophagy is strongly regarded to be one of the major pathogenic mechanisms of AD, it is necessary to review how the AD-associated genes are related to autophagy. We anticipate our current review to be a starting point for future studies regarding AD-associated genes and autophagy.

*This article is part of a Special Issue entitled SI:Autophagy.*

© 2016 Elsevier B.V. All rights reserved.

## Contents

1. Introduction	202
1.1. Alzheimer's disease	202
1.2. Autophagy	202
1.3. Autophagy in AD	202
2. Autophagy-related features and roles of AD-associated genes	202
2.1. Genes associated with AD	202
2.2. APP and Aβ	202
2.3. Presenilin	202
2.4. ADAM10	203
2.5. TAU	204
2.6. APOE	204
2.7. TREM2	204
2.8. PICALM	204
2.9. Clusterin	204

**Abbreviations:** AD, Alzheimer's disease; APP, amyloid precursor protein; Aβ, β-amyloid; PS1/2, presenilin 1/2; ApoE, apolipoprotein E; ADAM10, a disintegrin and metallopeptidase domain 10; TREM2, triggering receptor expressed on myeloid cells 2; BECN1, beclin-1; SNP, single nucleotide polymorphism; PICALM, phosphatidylinositol-binding clathrin assembly protein; CR1, complement component 3b/4b receptor 1; BIN1, bridging integrator 1; MS4A6A/E, membrane-spanning 4 domains subfamily A/E member 6A; ABCA7, ATP-binding cassette subfamily A member 7; CD2AP, CD2-associated protein; EPHA1, ephrin receptor A1; EPHB2, ephrin receptor B2; HLA-DRB5/1, major histocompatibility complex class II DRβ5/1; SORL1, sortilin-related receptor L A repeats containing; PTK2B, protein tyrosine kinase 2β; SLC24A4, solute carrier family 24 member 4; ZCWPW1, zinc finger CW-type with PWWP domain 1; CELF1, CUGBP Elav-like family member 1; FERMT2, fermitin family member 2; CASS4, Cas scaffolding protein family member 4; INPP5D, inositol polyphosphate-5 phosphatase 145 kDa; MEF2c, myocyte enhancer factor 2C; NME8, NME/NM23 family member 8; PLD3, phospholipase D3

\* Corresponding authors at: Alzheimer Disease Experts Lab (ADEL), Department of Brain Science, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul 138-736, Republic of Korea.

E-mail addresses: [ysy@amc.seoul.kr](mailto:ysy@amc.seoul.kr) (S.-Y. Yoon), [dhkim@amc.seoul.kr](mailto:dhkim@amc.seoul.kr) (D.-H. Kim).

<http://dx.doi.org/10.1016/j.brainres.2016.03.018>

0006-8993/© 2016 Elsevier B.V. All rights reserved.

2.10.	CD2AP .....	204
2.11.	Ephrin A1 .....	205
2.12.	PLD3 .....	205
2.13.	SORL1 .....	205
2.14.	BIN1 .....	205
2.15.	Other AD-related genes .....	206
3.	Conclusions .....	206
	Acknowledgments .....	206
	References .....	206

## 1. Introduction

### 1.1. Alzheimer's disease

Alzheimer's disease (AD), the most common neurodegenerative disease, is characterized by progressive impairment of cognitive function and memory formation. Pathological signalling in AD is largely mediated by two major characteristic components, neurofibrillary tangles (NFTs) and senile plaques (Gomez-Isla et al., 1997). Extracellular plaques are primarily composed of amyloid- $\beta$  ( $A\beta$ ) peptides, which are derived from amyloid precursor protein (APP) via proteolytic processing. NFTs are formed by intraneuronal accumulation of paired helical filaments composed of abnormally hyperphosphorylated TAU protein (Grundke-Iqbal et al., 1986).

### 1.2. Autophagy

Macroautophagy (hereafter, autophagy) is a catabolic process that sequesters cytoplasm, including aberrant organelles and macromolecules, into double-membrane vesicles and delivers this material to lysosomes for degradation and the eventual recycling of the resulting macromolecules (Castellano et al., 2011b). Under the control of various signalling and protein assemblies from certain stimuli, such as starvation, damaged organelles, or protein aggregates, the first step of autophagy begins with the formation of an isolation membrane (phagophore). The isolation membrane elongates around the molecules and organelles to be degraded, closing its inner and outer bilayers to form a double-membrane autophagosome. The autophagosome then fuses with a lysosome that degrades the autophagosome contents (Hale et al., 2013; Klionsky, 2012). Impairment or misregulation in these steps of autophagy is associated with many neurodegenerative diseases, including AD (Nixon, 2013).

### 1.3. Autophagy in AD

Marked accumulation of autophagosomes and late autophagic vacuoles is observed in dystrophic neurites of AD brains, animal AD model brains, and AD cellular models, suggesting impaired fusion with or degradation by lysosomes (Yoon et al., 2008; Yu et al., 2004, 2005). Nixon (2013) recently reviewed the relationship between impaired lysosomal function and autophagy in neurodegenerative diseases, including AD. In our present review, we discuss the association of AD genes with autophagy in an attempt to understand how autophagy is involved in the pathogenesis of AD and how therapeutic approaches for AD could exploit autophagic pathways.

## 2. Autophagy-related features and roles of AD-associated genes

### 2.1. Genes associated with AD

The classical genes associated with early-onset familial AD are

APP, presenilin 1 (PS1), and presenilin 2 (PS2). Apolipoprotein E (APOE) is the strongest risk factor for late-onset AD (Guerreiro et al., 2013b; Karch and Goate, 2015). Recent genetic studies have identified numerous novel gene loci affecting late-onset AD (Table 1).

### 2.2. APP and $A\beta$

APP is a type I membrane protein that is sequentially cleaved by  $\beta$ -secretase and  $\gamma$ -secretase to generate  $A\beta$  peptide, a major constituent of the senile plaques of AD. More than 30 mutations in APP are associated with early-onset familial AD (Guerreiro et al., 2012; <http://www.molgen.vib-ua.be/ADMutations>). Autophagy has been suggested to lead to  $A\beta$  generation since the first report proposing the role of autophagy in AD because early studies demonstrated that autophagosomes accumulate within AD neurites, and APP, CTFs of APP,  $A\beta$ , and BACE were found within these autophagosomes (Mizushima, 2005; Nixon, 2007; Yu et al., 2004, 2005). However, further understanding of autophagy itself and its relationship with AD led to the identification of APP,  $A\beta$ , APP-CTFs, and BACE as autophagy substrates (Cho et al., 2014; Jaeger et al., 2010; Liu et al., 2013; Lunemann et al., 2007; Pickford et al., 2008; Tian et al., 2013; Zhou et al., 2011). In support of this view, various compounds, such as rapamycin, trehalose, carbamazepine, latrepirdine, arctigenin, temsirolimus, and curcumin, have been suggested to help protect against AD by degrading  $A\beta$  and other related pathogenic proteins via activation of autophagy (Jiang et al., 2014a; Li et al., 2013; Peruchio et al., 2012; Steele and Gandy, 2013; Tian et al., 2011; Wang et al., 2014; Zhu et al., 2013).

A direct role of APP or  $A\beta$  in autophagy has not been determined yet, but AD-related mutations in APP may contribute to AD pathogenesis by producing impaired autophagy functions. Such mutations are known to generate more  $A\beta$  and aggregation-prone  $A\beta$ , which results in an overloaded autophagic pathway due to accumulated substrates.  $A\beta$  directly interacts with membranes via its hydrophobic carboxyl terminus (Masters and Selkoe, 2012), which is suggested to interfere with normal biogenesis and trafficking of intracellular organelles (Kakio et al., 2004; Murphy, 2007; Sasahara et al., 2013). This feature of  $A\beta$  may also affect the biogenesis or trafficking of autophagosomes and their fusion with lysosomes, and this possibility needs to be addressed in the future.  $A\beta$  accumulation in lysosomes results in lysosomal membrane destabilization and leakage (Ji et al., 2002; Yang et al., 1998), which may also impair autophagy and lysosomal degradation (Nixon, 2013).

### 2.3. Presenilin

Presenilins 1 and 2 are homologous integral membrane proteins containing nine transmembrane domains (Guerreiro et al., 2012). Presenilin 1/2 forms the  $\gamma$ -secretase complex with nicastrin, anterior pharynx-defective 1 (APH1A/B), and presenilin enhancer 2 (PEN2) to cleave APP into  $A\beta$  (Wakabayashi and De Strooper,

Download English Version:

<https://daneshyari.com/en/article/4323516>

Download Persian Version:

<https://daneshyari.com/article/4323516>

[Daneshyari.com](https://daneshyari.com)